We present a case of a 50-year-old man with COVID-19 infection and acute respiratory
distress syndrome as a result of a cytokine storm and use of anakinra, an interleukin 1 …

Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant
inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a …

Background Coronaviruses can induce the production of interleukin (IL)-1β, IL-6, tumour
necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been …

Background The potential risk of cytokine storm in patients with coronavirus disease 2019
(COVID-19) has been described [1]; we write to share our experience treating a 17-year-old …

Introduction Little evidence appears to exist for the use of anakinra, a recombinant
interleukin-1 receptor antagonist, after non-response to treatment with corticosteroids alone …

Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute
respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of …

Introduction Hyperinflammatory state has a role in the pathogenesis of COVID‐19. Anakinra
could reduce inflammation and help to combat the condition. In this study, we aimed to …

The hyperinflammatory state leading to an aberrant cytokine production, culminating in
acute respiratory distress syndrome, sepsis and multi-organ dysfunction contribute much to …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a recently discovered
coronavirus, is responsible for COVID-19, a newly emerged disease that has become …

Introduction Severe COVID-19 cases have a detrimental hyper-inflammatory host response
and different cytokine-blocking biologic agents were explored to improve outcomes …